CNS
Shire signs CNS disorders deal with Heptares
March 23, 2012Research and Development A2A, CNS, GPCR, Heptares, Shire
Shire is to develop and commercialise a novel adenosine A2A antagonist discovered by Heptares currently in pre-clinical development.UK-based Heptares discovers and …
Lundbeck and Otsuka to collaborate in CNS
November 11, 2011Research and Development, Sales and Marketing Abilify, CNS, Lundbeck, Otsuka
Lundbeck and Otsuka have signed a major collaborative deal to sell and develop up to five CNS drugs, including a …
Lundbeck establishes research centre in China
October 18, 2011Research and Development Brain disorders, CNS, China, Lundbeck, Shanghai, emerging markets
Lundbeck has set up a new research centre in China, joining a wave of pharma companies investing in the region. The …
UCB teams up with Harvard for CNS research
March 2, 2011Research and Development CNS, Harvard, UCB, academia, academic research, immunology
UCB has signed a new research collaboration with Harvard University that will focus on central nervous system and immunology therapies. …
Evotec wins grant to advance H3 receptor antagonist
May 4, 2010Research and Development CNS, Evotec, MS
Evotec is to receive funding of up to 1.5 million euros from a German government fund to advance its H3 …
Roche and PTC sign CNS research deal
September 4, 2009Research and Development CNS, Roche
PTC Therapeutics has signed an early-stage drug discovery deal with Roche that will focus on treatments for central nervous system …
Boehringer collaboration targets Alzheimer’s
June 18, 2009Research and Development, Sales and Marketing Boehringer, CNS
Boehringer Ingelheim and Pennsylvania-based Vitae Pharmaceuticals have signed a global agreement to develop novel treatments for Alzheimer's. The disease currently …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
